Autologous blood transfusion using recombinant human erythropoietin in gastrointestinal surgery.

为预防同种异体输血（HBT）的不良反应，我们对接受胃肠道手术的夫妇进行了重组人促红细胞生成素（EPO）治疗，并与自体献血（ABD）进行了比较。我们还检测了这些患者的内源性EPO：1）检测的癌症患者的EPO水平相对低于缺铁性贫血患者。2）每日给予重组EPO（三、000-6000 IU），使Hb浓度提高约1.0 g/dl; 3）自体血存款（400-600 ml）与EPO（3000 IU）联用，Hb浓度增加0.8 g/dl，与单用EPO基本相同。然而，由于自体血液存款诱导医务人员不进行HBT，并且施用EPO显著提高Hb浓度，因此自体血液捐献与施用重组EPO一起有望减少HBT的副作用，从而防止HBT的副作用。

To prevent adverse effects of homologous blood transfusion (HBT), we administered recombinant human erythropoietin (EPO) to the patients undergoing gastrointestinal surgery couples with or without autologous blood donation (ABD). We also measured the endogenous EPO in these patients.1) The EPO level in cancer patients tested was found relatively lower than that in patients with iron deficiency anemia.2) Daily administration of recombinant EPO (3,000-6000 IU) for 7 days prior operation raised Hb consentration in patients by approximately 1.0 g/dl.3) Autologous blood deposit (400-600 ml) coupled with adoministration of EPO (3000 IU) also raised Hb concentration increment by 0.8 g/dl, which was essentially same with that of EPO adoministration alone. However, since autologous blood deposit induces medical staffs not to perform HBT and administration of EPO substantially raises Hb concentration, autologous blood donation together with administration of recombinant EPO promises reduction and thereby prevention of adverse effects of HBT.